DHDavid O. Hodge

David O. Hodge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


David O. Hodge has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Risk of Obstructive Sleep Apnea in Open-Angle Glaucoma: A Population-Based Cohort Study

    by Marybeth K. Farazdaghi, Kenny Y. Wang, Timothy T. Xu, Eric J. Olson, Sasha A. Mansukhani, Launia J. White, David O. Hodge, Arthur J. Sit

    Precis: In this retrospective population-based cohort study, patients with open-angle glaucoma were more likely to develop obstructive sleep apnea than matched controls from the general population of Olmsted County, Minnesota. Purpose: To investigate the risk of obstructive sleep apnea (OSA) in patients with open-angle glaucoma (OAG) compared to the risk of OSA in matched controls from a general population. Patients and Methods: Retrospective population-based case-control study comparing the incidence of OSA with a diagnosis of OAG (cases) to the incidence of OSA in matched patients without OAG (controls) from Olmsted County, Minnesota between January 1, 1980 and December 31, 2018. Patients were identified using the Rochester Epidemiology Project. Medical records were reviewed to confirm OAG diagnoses. OSA diagnoses were based on sleep study data and polysomnography parameters. Cumulative probability of OSA was estimated using the Kaplan-Meier method. Results: This cohort had 7,000 patients: 3,500 case patients with OAG diagnosed at any time point, and 3,500 matched control subjects without OAG, with all OAG and OSA diagnoses manually confirmed. There was no statistically significant difference of OSA frequency prior to index date in cases versus controls ( P =0.52). There were 371 (12.5%) cases who developed OSA after glaucoma diagnosis compared to 297 (10.2%) patients who were diagnosed with OSA after the index date ( P =0.0068). The multivariate hazard ratio for diagnosis of OSA after OAG diagnosis was 1.17 ( P =0.047, 95% CI: 1.00, 1.36). The 10-year absolute risk of OSA after OAG diagnosis was 12.5%, and risk of OSA increased with time. Conclusion: In this population-based study, patients with OAG were more likely to be diagnosed with OSA compared to patients without OAG, suggesting a possible association that may justify increased clinical awareness.

  • Open Access

    Incidence and Outcomes of Atrial Arrhythmia with CDK4/6 Inhibitors in HR-Positive / HER2-Negative Breast Cancer

    by Nathaniel E. Davis, Joerg Herrmann, David O. Hodge, Sophia Blumenfeld, Kathryn J. Ruddy, Nicholas Yick Loong Tan

    Background: Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are increasingly used in hormone receptor-positive, HER2-negative (HR+/HER2−) breast cancer, yet emerging data suggest potential cardiotoxicity, including atrial arrhythmias (AA). Understanding the incidence and outcomes of AA in this population is essential as indications for CDK4/6 inhibitors expand. Objectives: To evaluate the incidence of new-onset AA and associated outcomes in patients with HR+/HER2− breast cancer treated with CDK4/6 inhibitors. Methods: We conducted a retrospective cohort study of patients treated at Mayo Clinic from 2015– 2024 who received CDK4/6 inhibitors for HR+/HER2− breast cancer. The primary outcome was incidence of AA (atrial fibrillation, atrial flutter, or atrial tachycardia). Secondary outcomes included cerebrovascular events and all-cause mortality. Kaplan-Meier estimates and Cox regression models were used to assess outcomes and associated risk factors. Results: Among 2,782 patients, 59% received palbociclib, 28% abemaciclib, and 14% ribociclib. New-onset AA occurred in 45, with cumulative incidence at 5 years of 2.8%. No significant differences in AA incidence were observed between agents (p=0.44). Multivariate analysis identified age at treatment as the only independent predictor of AA (HR 1.073, p<0.001). Four patients with new-onset AA experienced cerebrovascular events. New-onset AA was associated with increased mortality (HR 1.56, p=0.012). Conclusions: CDK4/6 inhibitor therapy was associated with a low but clinically significant risk of new-onset AA, which in turn is associated with increased mortality. There was no significant difference in new-onset AA risk between different individual CDK4/6 inhibitor agents. Prospective studies are needed to define mechanisms and guide monitoring strategies.

  • Optimal Target of Activated Clotting Time During PCI and Outcomes: The OPTIMAL-ACT Trial

    by S. Michael Gharacholou, Colleen S. Thomas, David O. Hodge, Abdallah El Sabbagh, Gary E. Lane, Peter M. Pollak, Dilip P. Pillai, Gretchen Johns, Leslie J. Donato, Mandeep Singh

  • Open Access

    Cardiac Troponin T Elevation Predicts Mortality in Hospitalized COVID-19 Patients

    by Katelyn A. Bruno, R. Scott Wright, Joshua Culberson, Mikolaj A. Wieczorek, David O. Hodge, Patrick W. Johnson, Yomary A. Jimenez, Emily R. Whelan, Jose M. Malavet, Kathryn F. Larson, et al.

    Objective To evaluate if cardiac troponin values predict poor outcomes in COVID-19 patients across the range of patients of different sex and age. Methods We examined high-sensitivity cardiac troponin T (hs-cTnT) levels in 1,050 severely ill hospitalized COVID-19 patients who had hs-cTnT data available and participated in the Expanded Access Program for convalescent plasma study during the first wave (April-August 2020) of the COVID-19 pandemic. Results We observed a continuous relationship between hs-cTnT levels and mortality in hospitalized males and females with COVID-19. This finding was present regardless of sex or age. Conclusion These data indicate the prognostic ability of hs-cTnT to predict mortality in hospitalized COVID-19 patients across all relevant patient groups. Clinical Trials registration number NCT04338360 Clinical Perspective This study evaluated the prognostic value of elevated hs-cTnT in patients hospitalized with COVID-19 who received convalescent plasma. There was a continuous relationship between elevated hs-cTnT values and mortality in both males and females hospitalized for COVID-19. The magnitude of the prognostic value of elevated hs-cTnT varied by sex and age, suggesting that these covariates are important to consider in this population.

  • Open Access

    Significant Microvascular Abnormalities Present in Autonomic Nervous System Dysfunction: Results of a Cross-Sectional Study

    by Sehreen Mumtaz, Karissa Arca, Vikas Majithia, William Cheshire, David Hodge, Florentina Berianu

    Purpose: The prevalence and phenotype of capillaroscopic abnormalities in patients with autonomic nervous system dysfunction have not yet been investigated. Multiorgan involvement in dysautonomia entails abnormal vasoreactivity. We aim to correlate the diagnosis of autonomic dysfunction with certain clinical manifestations, which may provide prognostic or diagnostic information using a noninvasive technique, i.e., nailfold video capillaroscopy (NVC). Methods: Patients with autonomic nervous system dysfunction were recruited from rheumatology and neurology clinics with voluntary NVC procedures from 31 January 2024 to 10 January 2024, and a comparison with normal controls was performed. Additional recorded information include demographics and diagnoses of autonomic dysfunction types by autonomic testing, including, but not limited to, the following: reflex screen, sweat test, Valsalva maneuver, nerve fiber density, electromyography (EMG), serology, and history of autoimmune diseases. NVC was performed on a total of 27 patients. This study was approved by the Mayo Clinic Institutional Review Board. Results: The autonomic dysfunction group consisted of small-fiber neuropathy (37%), orthostatic hypotension (48%), autonomic neuropathy (30%), limited autonomic neuropathy (7%), postural orthostatic tachycardia syndrome (POTS) (7%), and connective tissue disease (7%), among other types. Patients with autonomic dysfunction had statistically significant increases in microhemorrhages, dilated capillaries, and ramifications when compared to controls. Conclusions: Autonomic dysfunction was associated with statistically significant microvascular abnormalities compared to normal controls with a distinct NVC pattern. There was a statistically significant correlation between age and BMI with microvascular abnormalities. Here, we demonstrate the diagnostic potential of NVC in autonomic dysfunction and advocate for further study of capillary structures in autonomic dysfunction.


  • Prenatal Antidepressant Exposure and Risk of Depression and Anxiety Disorders: An Electronic Health Records–Based Cohort Study

    by Ardesheer Talati, Jennifer L. Vande Voort, Launia J. White, David Hodge, Cynthia J. Stoppel, Myrna M. Weissman, Jay A. Gingrich, William V. Bobo


  • Open Access

    Topography of ischemic strokes in cancer-associated non-bacterial thrombotic endocarditis: A single-institution descriptive case series

    by Carlee I. Oakley, Ewa M. Wysokinska, Alicja Kaminska, Marwa A. Mohammed, Patryk Patrzalek, Damon Houghton, David Hodge, Waleed Brinjikji, James P. Klaas, Waldemar E. Wysokinski


  • Echocardiography Screening of Consecutive Patients With Portal Hypertension Referred to Mayo Clinic for Liver Transplant Evaluation

    by Charles D. Burger, Hollie Saunders, David O. Hodge, Robert E. Safford, Scott A. Helgeson, John E. Moss, Hilary M. DuBrock, Rodrigo Cartin-Ceba, Hector R. Cajigas, Michael J. Krowka


  • Open Access

    Projected Incidence of Hepatobiliary Cancers and Trends Based on Age, Race, and Gender in the United States

    by Michael H. Storandt, Sri Harsha Tella, Mikolaj A. Wieczorek, David Hodge, Julia K. Elrod, Philip S. Rosenberg, Zhaohui Jin, Amit Mahipal

    Background: Identifying the projected incidence of hepatobiliary cancers and recognizing patient cohorts at increased risk can help develop targeted interventions and resource allocation. The expected incidence of subtypes of hepatobiliary cancers in different age groups, races, and genders remains unknown. Methods: Historical epidemiological data from the Surveillance, Epidemiology, and End Results (SEER) database was used to project future incidence of hepatobiliary malignancies in the United States and identify trends by age, race, and gender. Patients ≄18 years of age diagnosed with a hepatobiliary malignancy between 2001 and 2017 were included. US Census Bureau 2017 National Population projects provided the projected population from 2017 to 2029. Age–Period–Cohort forecasting model was used to estimate future births cohort-specific incidence. All analyses were completed using R Statistical Software. Results: We included 110381 historical patients diagnosed with a hepatobiliary malignancy between 2001 and 2017 with the following subtypes: hepatocellular cancer (HCC) (68%), intrahepatic cholangiocarcinoma (iCCA) (11.5%), gallbladder cancer (GC) (8%), extrahepatic cholangiocarcinoma (eCCA) (7.6%), and ampullary cancer (AC) (4%). Our models predict the incidence of HCC to double (2001 to 2029) from 4.5 to 9.03 per 100,000, with the most significant increase anticipated in patients 70–79 years of age. In contrast, incidence is expected to continue to decline among the Asian population. Incidence of iCCA is projected to increase, especially in the white population, with rates in 2029 double those in 2001 (2.13 vs. 0.88 per 100,000, respectively; p < 0.001). The incidence of GC among the black population is expected to increase. The incidence of eCCA is expected to significantly increase, especially among the Hispanic population, while that of AC will remain stable. Discussion: The overall incidence of hepatobiliary malignancies is expected to increase in the coming years, with certain groups at increased risk. These findings may help with resource allocation when considering screening, treatment, and research in the coming years.


  • Catheter Ablation of Atrial Fibrillation in Adult Congenital Heart Disease: Procedural Characteristics and Outcomes

    by Tiffany Y. Hu, Chaitra Janga, Mustapha Amin, Nicholas Y. Tan, David O. Hodge, Ramila A. Mehta, Christopher J. McLeod, Anca Chiriac, William R. Miranda, Heidi M. Connolly, et al.

    BACKGROUND: The outcomes of catheter ablation for atrial fibrillation in adults with congenital heart disease are not well described. METHODS: In a retrospective study of adult patients with congenital heart disease who underwent catheter ablation for atrial fibrillation between 2000 and 2020 at Mayo Clinic, procedural characteristics and outcomes were collected. The primary outcomes were atrial arrhythmia (AA) recurrence following a 3-month blanking period and repeat ablation. An arrhythmia clinical severity score was assessed pre- and post-ablation based on the duration of arrhythmia episodes, symptoms, cardioversion frequency, and antiarrhythmic drug use. RESULTS: One hundred forty-five patients (age, 57±12 years; 28% female; 63% paroxysmal atrial fibrillation) underwent 198 ablations with a median follow-up of 26 months (interquartile range, 14–69). One hundred ten, 26, and 9 patients had simple, moderate, and complex congenital heart disease, respectively. All patients underwent pulmonary vein isolation, and non–pulmonary vein targets were ablated in 79 (54%). AA recurrence at 12 months was 37% (95% CI, 29%–45%). On univariate analysis, increasing left atrial volume index was associated with higher odds of AA recurrence (odds ratio, 1.03 [1.00–1.06] per 1 mL/m 2 increment; P =0.05). Noninducibility of atrial flutter was predictive of decreased odds of AA recurrence (odds ratio, 0.43 [0.21–0.90]; P =0.03). A second ablation was performed in 43 patients after a median of 20 (interquartile range, 8–37) months. Arrhythmia clinical severity scores improved following ablation, reflecting a decrease in symptoms, cardioversions, and antiarrhythmic drugs. CONCLUSIONS: Catheter ablation of atrial fibrillation is feasible and effective in patients with adult congenital heart disease and reduces symptoms. Recurrence of AA frequently requires repeat ablation.